Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy-Reference-Cited by-同舟云学术

Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy

Author:

Charles Angel¹,Bourne Christopher M.²^ORCID,Korontsvit Tanya¹,Aretz Zita E. H.³,Mun Sung Soo¹,Dao Tao¹,Klatt Martin G.¹,Scheinberg David A.¹⁴

Affiliation:

1. Molecular Pharmacology Program, Sloan Kettering Institute, New York, USA

2. Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine, New York, USA

3. Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, USA

4. Pharmacology Program, Weill Cornell Medicine, New York, USA

Funder

Deutsches Forschungszentrum für Gesundheit und Umwelt, Helmholtz Zentrum München

Doris Duke Charitable Foundation

National Institutes of Health

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

Reference39 articles.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献